89Zr-rituximab PET/CT for detection of central nervous system lymphoma

89Zr-rituximab PET/CT for detection of central nervous system lymphoma - ZoLa study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON42205

Enrollment

Registered

2015-08-19

Start date

2016-03-22

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain tumour lymphoma

Interventions

89Zr-rituximab PET/CT

central nervous system

lymphoma

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Patients who have signed informed consent - Age >= 18 years - MR suspicion of a primary CNS lymphoma (homogeneous contrast enhancement, low MRI ADC values).

Exclusion criteria

Exclusion criteria: - Pregnancy

Design outcomes

Primary

Measure	Time frame
The main outcome of the study is the performance of 89Zr- rituximab PET/CT in diagnosing CSN lymphoma. The diagnostic gold standard will be histological biopsy and pathology diagnosis of PCNSL.	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)